Article Versions Notes

Alburquerque-González B, Bernabé-García Á, Bernabé-García M, Ruiz-Sanz J, López-Calderón FF, Gonnelli L, Banci L, Peña-García J, Luque I, Nicolás FJ, et al. The FDA-Approved Antiviral Raltegravir Inhibits Fascin1-Dependent Invasion of Colorectal Tumor Cells In Vitro and In Vivo. Cancers. 2021; 13(4):861. https://doi.org/10.3390/cancers13040861

Alburquerque-González, Begoña, Ángel Bernabé-García, Manuel Bernabé-García, Javier Ruiz-Sanz, Fernando Feliciano López-Calderón, Leonardo Gonnelli, Lucia Banci, Jorge Peña-García, Irene Luque, Francisco José Nicolás, and et al. 2021. "The FDA-Approved Antiviral Raltegravir Inhibits Fascin1-Dependent Invasion of Colorectal Tumor Cells In Vitro and In Vivo" Cancers 13, no. 4: 861. https://doi.org/10.3390/cancers13040861

Alburquerque-González, B., Bernabé-García, Á., Bernabé-García, M., Ruiz-Sanz, J., López-Calderón, F. F., Gonnelli, L., Banci, L., Peña-García, J., Luque, I., Nicolás, F. J., Cayuela-Fuentes, M. L., Luchinat, E., Pérez-Sánchez, H., Montoro-García, S., & Conesa-Zamora, P. (2021). The FDA-Approved Antiviral Raltegravir Inhibits Fascin1-Dependent Invasion of Colorectal Tumor Cells In Vitro and In Vivo. Cancers, 13(4), 861. https://doi.org/10.3390/cancers13040861